乌帕替尼对老年IBD心血管风险患者心血管事件及血脂的影响
研究纳入50岁及以上有心血管基线风险的IBD患者,纵向评估乌帕替尼治疗期间血脂、动脉粥样硬化性心血管疾病风险评分及不良事件。低密度脂蛋白早期升高后稳定,高密度脂蛋白升高,二者比值无变化;动脉粥样硬化性心血管疾病风险轻度增加(+1.2%),188患者年内无主要不良心血管事件,活动性疾病期间发生2例静脉血栓栓塞。
要点
- 乌帕替尼治疗老年IBD心血管风险患者188患者年内无主要不良心血管事件。
- 低密度脂蛋白早期升高后稳定,高密度脂蛋白升高,二者比值无变化。
- 动脉粥样硬化性心血管疾病风险轻度增加(+1.2%),活动性疾病期间发生2例静脉血栓栓塞。
核心结论
- 在50岁及以上有心血管基线风险的IBD患者中,乌帕替尼治疗188患者年内未发生主要不良心血管事件。
- 研究支持在风险监测下适当临床使用乌帕替尼。
研究设计与样本
- 研究纳入50岁及以上开始乌帕替尼治疗的IBD患者。
- 纵向评估血脂、动脉粥样硬化性心血管疾病风险评分及不良事件。
主要发现
- 低密度脂蛋白早期升高但随后稳定,高密度脂蛋白升高,低密度脂蛋白与高密度脂蛋白比值无变化。
- 动脉粥样硬化性心血管疾病风险轻度增加(+1.2%)。
- 未发生主要不良心血管事件。
- 活动性疾病期间发生2例静脉血栓栓塞事件。
临床怎么用
- 对50岁及以上有心血管基线风险的IBD患者使用乌帕替尼时,应进行风险监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Regulatory safety warnings for Janus kinase inhibitors, based on increased cardiovascular events in the rheumatoid arthritis populations, have raised concern regarding their use in inflammatory bowel disease (IBD) patients with cardiovascular risk factors. METHODS: Patients 50 years and older with IBD initiating upadacitinib were studied. Lipids, atherosclerotic cardiovascular disease risk scores, and adverse events were longitudinally assessed. RESULTS: Low-density lipoprotein increased early but stabilized, whereas high-density lipoprotein increased, with no change in low-density lipoprotein:high-density lipoprotein ratio. Atherosclerotic cardiovascular disease risk increased modestly (+1.2%). No major adverse cardiovascular events occurred. Two venous thromboembolism events occurred during active disease. DISCUSSION: In older patients with IBD and baseline cardiovascular risk, upadacitinib was not associated with cardiovascular events over 188 patient-years, supporting appropriate clinical use with risk monitoring.
引用
- Choden T, Mathew AJ, Goffinet A, et al. Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk. Am J Gastroenterol. 2026. PMID: 42262536. doi:10.14309/ajg.0000000000004074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。